Aktis Oncology (AKTS) Form 3 stake disclosed by Vida Ventures LLC
Rhea-AI Filing Summary
Vida Ventures II, LLC and Vida Ventures II-A, LLC filed an initial Form 3 as 10% owners of Aktis Oncology, Inc. (AKTS), reporting indirect holdings of the company’s preferred stock. The filing shows Series A and Series B Redeemable Convertible Preferred Stock that each convert into common stock on a 3.8044-for-1 basis with no expiration date. All shares of both preferred series will automatically convert into common stock immediately prior to the closing of Aktis Oncology’s initial public offering, without any additional payment. The shares are held through Vida Ventures II and Vida Ventures II-A, with management entities and committee members disclaiming beneficial ownership beyond their pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Vida Ventures II, LLC, VIDA VENTURES II-A, LLC
Role
10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Redeemable Convertible Preferred Stock | -- | -- | -- |
| holding | Series A Redeemable Convertible Preferred Stock | -- | -- | -- |
| holding | Series B Redeemable Convertible Preferred Stock | -- | -- | -- |
| holding | Series B Redeemable Convertible Preferred Stock | -- | -- | -- |
Holdings After Transaction:
Series A Redeemable Convertible Preferred Stock — 4,008,513 shares (Indirect, See Footnote);
Series B Redeemable Convertible Preferred Stock — 985,699 shares (Indirect, See Footnote)
Footnotes (4)
- F1. Each share of Series A Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and has no expiration date. All shares of Series A Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.
- F2. These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
- F3. These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and Helen Kim, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
- F4. Each share of Series B Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and has no expiration date. All shares of Series B Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Aktis Oncology (AKTS) Form 3 filed by Vida Ventures report?
It reports that Vida Ventures II, LLC and Vida Ventures II-A, LLC are 10% owners of Aktis Oncology, Inc. through holdings of Series A and Series B Redeemable Convertible Preferred Stock.
Does this AKTS Form 3 show a new purchase or sale by Vida Ventures?
No. As a Form 3, it serves as an initial statement of beneficial ownership and, in the provided data, the transactions are coded as holdings rather than new purchases or sales.